Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1996 Jan;49(1):57–64. doi: 10.1136/jcp.49.1.57

Prognostic value of cathepsin D in breast cancer: comparison of immunohistochemical and immunoradiometric detection methods.

U J Göhring 1, A Scharl 1, U Thelen 1, A Ahr 1, G Crombach 1, B R Titius 1
PMCID: PMC1023159  PMID: 8666688

Abstract

AIM: To test whether immunoradiometric or immunohistochemical detection of lysosomal protease cathepsin D in breast cancer is more predictive of outcome. METHODS: Tumour tissues from 270 primary breast cancer patients were evaluated for the expression of cathepsin D using immunohistochemistry (IH; paraffin embedded tissues) and an immunoradiometric assay (IRMA; cytosol from frozen tissues). Immunohistochemical scores were based on immunoreaction in tumour cells and tumour associated macrophages. RESULTS: IRMA values (cut off 40 fmol/mg cell protein) correlated significantly with IH values. Recorded incidences of positive immunoreaction in tumour cells using two different cut off values were 52% and 35%, respectively. Macrophages stained positive in 31% of tissues. Combined evaluation of tumour cells and macrophages resulted in positivity rates of 59% and 48%, respectively. Node status was the only variable found to correlate with cathepsin D expression. IH results correlated significantly with clinical outcome (median observation time 68 months) in node negative patients (n = 120) but not in node positive patients (n = 145). Cathepsin D positivity as measured by IRMA was not related to clinical outcome in either group. On multivariate analysis in the node negative group, IH detection of cathepsin D appeared to be the only independent factor indicating prognosis. For node positive patients, tumour grade, size, and receptor status were of prognostic relevance. CONCLUSIONS: Because of the simple methodology and the minimal amount of tissue used for analysis, immunohistochemistry was preferred to immunoradiometry for cathepsin D measurement; it also provided more predictive data with respect to prognosis.

Full text

PDF
57

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armas O. A., Gerald W. L., Lesser M. L., Arroyo C. D., Norton L., Rosen P. P. Immunohistochemical detection of cathepsin D in T2N0M0 breast carcinoma. Am J Surg Pathol. 1994 Feb;18(2):158–166. doi: 10.1097/00000478-199402000-00005. [DOI] [PubMed] [Google Scholar]
  2. Briozzo P., Badet J., Capony F., Pieri I., Montcourrier P., Barritault D., Rochefort H. MCF7 mammary cancer cells respond to bFGF and internalize it following its release from extracellular matrix: a permissive role of cathepsin D. Exp Cell Res. 1991 Jun;194(2):252–259. doi: 10.1016/0014-4827(91)90362-x. [DOI] [PubMed] [Google Scholar]
  3. Capony F., Morisset M., Barrett A. J., Capony J. P., Broquet P., Vignon F., Chambon M., Louisot P., Rochefort H. Phosphorylation, glycosylation, and proteolytic activity of the 52-kD estrogen-induced protein secreted by MCF7 cells. J Cell Biol. 1987 Feb;104(2):253–262. doi: 10.1083/jcb.104.2.253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Castiglioni T., Merino M. J., Elsner B., Lah T. T., Sloane B. F., Emmert-Buck M. R. Immunohistochemical analysis of cathepsins D, B, and L in human breast cancer. Hum Pathol. 1994 Sep;25(9):857–862. doi: 10.1016/0046-8177(94)90003-5. [DOI] [PubMed] [Google Scholar]
  5. Cowan W. K., Angus B., Henry J., Corbett I. P., Reid W. A., Horne C. H. Immunohistochemical and other features of breast carcinomas presenting clinically compared with those detected by cancer screening. Br J Cancer. 1991 Oct;64(4):780–784. doi: 10.1038/bjc.1991.398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Crombach G., Ingenhorst A., Göhring U. J., Scharl A., Schaeffer H. J., Stützer H., Bolte A. Prognostische Bedeutung von Kathepsin D beim primären Mammakarzinom. Geburtshilfe Frauenheilkd. 1994 Oct;54(10):545–551. doi: 10.1055/s-2007-1022337. [DOI] [PubMed] [Google Scholar]
  7. Domagala W., Markiewski M., Kubiak R., Bartkowiak J., Osborn M. Immunohistochemical profile of invasive lobular carcinoma of the breast: predominantly vimentin and p53 protein negative, cathepsin D and oestrogen receptor positive. Virchows Arch A Pathol Anat Histopathol. 1993;423(6):497–502. doi: 10.1007/BF01606541. [DOI] [PubMed] [Google Scholar]
  8. Duffy M. J., Reilly D., Brouillet J. P., McDermott E. W., Faul C., O'Higgins N., Fennelly J. J., Maudelonde T., Rochefort H. Cathepsin D concentration in breast cancer cytosols: correlation with disease-free interval and overall survival. Clin Chem. 1992 Oct;38(10):2114–2116. [PubMed] [Google Scholar]
  9. Eng Tan P., Benz C. C., Dollbaum C., Moore D. H., 2nd, Edgerton S. M., Zava D. T., Thor A. D. Prognostic value of Cathepsin D expression in breast cancer: immunohistochemical assessment and correlation with radiometric assay. Ann Oncol. 1994 Apr;5(4):329–336. doi: 10.1093/oxfordjournals.annonc.a058836. [DOI] [PubMed] [Google Scholar]
  10. Faust P. L., Kornfeld S., Chirgwin J. M. Cloning and sequence analysis of cDNA for human cathepsin D. Proc Natl Acad Sci U S A. 1985 Aug;82(15):4910–4914. doi: 10.1073/pnas.82.15.4910. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Foucré D., Bouchet C., Hacène K., Pourreau-Schneider N., Gentile A., Martin P. M., Desplaces A., Oglobine J. Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours. Br J Cancer. 1991 Nov;64(5):926–932. doi: 10.1038/bjc.1991.428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Garcia M., Capony F., Derocq D., Simon D., Pau B., Rochefort H. Characterization of monoclonal antibodies to the estrogen-regulated Mr 52,000 glycoprotein and their use in MCF7 cells. Cancer Res. 1985 Feb;45(2):709–716. [PubMed] [Google Scholar]
  13. Garcia M., Lacombe M. J., Duplay H., Cavailles V., Derocq D., Delarue J. C., Krebs B., Contesso G., Sancho-Garnier H., Richer G. Immunohistochemical distribution of the 52-kDa protein in mammary tumors: a marker associated with cell proliferation rather than with hormone responsiveness. J Steroid Biochem. 1987;27(1-3):439–445. doi: 10.1016/0022-4731(87)90338-4. [DOI] [PubMed] [Google Scholar]
  14. Garcia M., Salazar-Retana G., Pages A., Richer G., Domergue J., Pages A. M., Cavalie G., Martin J. M., Lamarque J. L., Pau B. Distribution of the Mr 52,000 estrogen-regulated protein in benign breast diseases and other tissues by immunohistochemistry. Cancer Res. 1986 Jul;46(7):3734–3738. [PubMed] [Google Scholar]
  15. Granata G., Coradini D., Cappelletti V., Di Fronzo G. Prognostic relevance of cathepsin D versus oestrogen receptors in node negative breast cancers. Eur J Cancer. 1991;27(8):970–972. doi: 10.1016/0277-5379(91)90260-k. [DOI] [PubMed] [Google Scholar]
  16. Göhring U. J., Ingenhorst A., Crombach G., Scharl A. Kathepsin-D-Expression im primären Mammakarzinom. Vergleich immunohistochemischer und biochemischer Ergebnisse. Pathologe. 1993 Dec;14(6):313–317. [PubMed] [Google Scholar]
  17. Henry J. A., McCarthy A. L., Angus B., Westley B. R., May F. E., Nicholson S., Cairns J., Harris A. L., Horne C. H. Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. An immunohistochemical study. Cancer. 1990 Jan 15;65(2):265–271. doi: 10.1002/1097-0142(19900115)65:2<265::aid-cncr2820650214>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  18. Hsu S. M., Raine L., Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981 Apr;29(4):577–580. doi: 10.1177/29.4.6166661. [DOI] [PubMed] [Google Scholar]
  19. Isola J., Weitz S., Visakorpi T., Holli K., Shea R., Khabbaz N., Kallioniemi O. P. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. J Clin Oncol. 1993 Jan;11(1):36–43. doi: 10.1200/JCO.1993.11.1.36. [DOI] [PubMed] [Google Scholar]
  20. Kandalaft P. L., Chang K. L., Ahn C. W., Traweek S. T., Mehta P., Battifora H. Prognostic significance of immunohistochemical analysis of cathepsin D in low-stage breast cancer. Cancer. 1993 May 1;71(9):2756–2763. doi: 10.1002/1097-0142(19930501)71:9<2756::aid-cncr2820710912>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  21. Kute T. E., Shao Z. M., Sugg N. K., Long R. T., Russell G. B., Case L. D. Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays. Cancer Res. 1992 Oct 1;52(19):5198–5203. [PubMed] [Google Scholar]
  22. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  23. Mansour E. G., Ravdin P. M., Dressler L. Prognostic factors in early breast carcinoma. Cancer. 1994 Jul 1;74(1 Suppl):381–400. doi: 10.1002/cncr.2820741326. [DOI] [PubMed] [Google Scholar]
  24. Mathieu M., Rochefort H., Barenton B., Prebois C., Vignon F. Interactions of cathepsin-D and insulin-like growth factor-II (IGF-II) on the IGF-II/mannose-6-phosphate receptor in human breast cancer cells and possible consequences on mitogenic activity of IGF-II. Mol Endocrinol. 1990 Sep;4(9):1327–1335. doi: 10.1210/mend-4-9-1327. [DOI] [PubMed] [Google Scholar]
  25. Maudelonde T., Brouillet J. P., Roger P., Giraudier V., Pages A., Rochefort H. Immunostaining of cathepsin D in breast cancer: quantification by computerised image analysis and correlation with cytosolic assay. Eur J Cancer. 1992;28A(10):1686–1691. doi: 10.1016/0959-8049(92)90069-e. [DOI] [PubMed] [Google Scholar]
  26. McGuire W. L., Tandon A. K., Allred D. C., Chamness G. C., Clark G. M. How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst. 1990 Jun 20;82(12):1006–1015. doi: 10.1093/jnci/82.12.1006. [DOI] [PubMed] [Google Scholar]
  27. Namer M., Ramaioli A., Fontana X., Etienne M. C., Héry M., Jourlait A., Milano G., Frenay M., François E., Lapalus F. Prognostic value of total cathepsin D in breast tumors. A possible role in selection of chemoresistant patients. Breast Cancer Res Treat. 1991 Oct;19(2):85–93. doi: 10.1007/BF01980938. [DOI] [PubMed] [Google Scholar]
  28. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Pfisterer M., Burkart F., Jockers G., Meyer B., Regenass S., Burckhardt D., Schmitt H. E., Müller-Brand J., Skarvan K., Stulz P. Trial of low-dose aspirin plus dipyridamole versus anticoagulants for prevention of aortocoronary vein graft occlusion. Lancet. 1989 Jul 1;2(8653):1–7. doi: 10.1016/s0140-6736(89)90253-5. [DOI] [PubMed] [Google Scholar]
  30. Pujol P., Maudelonde T., Daures J. P., Rouanet P., Brouillet J. P., Pujol H., Rochefort H. A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol. Cancer. 1993 Mar 15;71(6):2006–2012. doi: 10.1002/1097-0142(19930315)71:6<2006::aid-cncr2820710614>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  31. Ravdin P. M., Tandon A. K., Allred D. C., Clark G. M., Fuqua S. A., Hilsenbeck S. H., Chamness G. C., Osborne C. K. Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol. 1994 Mar;12(3):467–474. doi: 10.1200/JCO.1994.12.3.467. [DOI] [PubMed] [Google Scholar]
  32. Remmele W., Sauer-Manthey J. Comparative biochemical and immunohistochemical studies on the cathepsin D content of human breast cancer. Virchows Arch A Pathol Anat Histopathol. 1993;422(6):467–473. doi: 10.1007/BF01606455. [DOI] [PubMed] [Google Scholar]
  33. Rochefort H., Capony F., Garcia M. Cathepsin D in breast cancer: from molecular and cellular biology to clinical applications. Cancer Cells. 1990 Dec;2(12):383–388. [PubMed] [Google Scholar]
  34. Rochefort H. Cathepsin D in breast cancer: a tissue marker associated with metastasis. Eur J Cancer. 1992;28A(11):1780–1783. doi: 10.1016/0959-8049(92)90003-k. [DOI] [PubMed] [Google Scholar]
  35. Rochefort H., Cavailles V., Augereau P., Capony F., Maudelonde T., Touitou I., Garcia M. Overexpression and hormonal regulation of pro-cathepsin D in mammary and endometrial cancer. J Steroid Biochem. 1989;34(1-6):177–182. doi: 10.1016/0022-4731(89)90080-0. [DOI] [PubMed] [Google Scholar]
  36. Roger P., Montcourrier P., Maudelonde T., Brouillet J. P., Pages A., Laffargue F., Rochefort H. Cathepsin D immunostaining in paraffin-embedded breast cancer cells and macrophages: correlation with cytosolic assay. Hum Pathol. 1994 Sep;25(9):863–871. doi: 10.1016/0046-8177(94)90004-3. [DOI] [PubMed] [Google Scholar]
  37. Rogier H., Freiss G., Besse M. G., Cavalié-Barthez G., Garcia M., Pau B., Rochefort H., Paolucci F. Two-site immunoenzymometric assay for the 52-kDa cathepsin D in cytosols of breast cancer tissues. Clin Chem. 1989 Jan;35(1):81–85. [PubMed] [Google Scholar]
  38. Rosner D., Lane W. W. Should all patients with node-negative breast cancer receive adjuvant therapy? Identifying additional subsets of low-risk patients who are highly curable by surgery alone. Cancer. 1991 Oct 1;68(7):1482–1494. doi: 10.1002/1097-0142(19911001)68:7<1482::aid-cncr2820680704>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  39. Scharl A., Vierbuchen M., Würz H. Immunhistochemischer Nachweis von Ostrogen- und Progesteronrezeptoren beim Mammakarzinom mit Hilfe monoklonaler Antikörper: Vergleich mit der biochemischen Rezeptoranalyse. Pathologe. 1989 Jan;10(1):31–38. [PubMed] [Google Scholar]
  40. Seshadri R., Horsfall D. J., Firgaira F., McCaul K., Setlur V., Chalmers A. H., Yeo R., Ingram D., Dawkins H., Hahnel R. The relative prognostic significance of total cathepsin D and HER-2/neu oncogene amplification in breast cancer. The South Australian Breast Cancer Study Group. Int J Cancer. 1994 Jan 2;56(1):61–65. doi: 10.1002/ijc.2910560112. [DOI] [PubMed] [Google Scholar]
  41. Stonelake P. S., Baker P. G., Gillespie W. M., Dunn J. A., Spooner D., Morrison J. M., Bundred N. J., Oates G. D., Lee M. J., Neoptolemos J. P. Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer. Eur J Cancer. 1994;30A(1):5–11. doi: 10.1016/s0959-8049(05)80008-5. [DOI] [PubMed] [Google Scholar]
  42. Tandon A. K., Clark G. M., Chamness G. C., Chirgwin J. M., McGuire W. L. Cathepsin D and prognosis in breast cancer. N Engl J Med. 1990 Feb 1;322(5):297–302. doi: 10.1056/NEJM199002013220504. [DOI] [PubMed] [Google Scholar]
  43. Thorpe S. M., Rochefort H., Garcia M., Freiss G., Christensen I. J., Khalaf S., Paolucci F., Pau B., Rasmussen B. B., Rose C. Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res. 1989 Nov 1;49(21):6008–6014. [PubMed] [Google Scholar]
  44. Têtu B., Brisson J., Côté C., Brisson S., Potvin D., Roberge N. Prognostic significance of cathepsin-D expression in node-positive breast carcinoma: an immunohistochemical study. Int J Cancer. 1993 Sep 30;55(3):429–435. doi: 10.1002/ijc.2910550318. [DOI] [PubMed] [Google Scholar]
  45. Veneroni S., Daidone M. G., Di Fronzo G., Cappelletti V., Amadori D., Riccobon A., Paradiso A., Correale M., Silvestrini R. Quantitative immunohistochemical determination of cathepsin-D and its relation with other variables. Breast Cancer Res Treat. 1993;26(1):7–13. doi: 10.1007/BF00682695. [DOI] [PubMed] [Google Scholar]
  46. Vignon F., Capony F., Chambon M., Freiss G., Garcia M., Rochefort H. Autocrine growth stimulation of the MCF 7 breast cancer cells by the estrogen-regulated 52 K protein. Endocrinology. 1986 Apr;118(4):1537–1545. doi: 10.1210/endo-118-4-1537. [DOI] [PubMed] [Google Scholar]
  47. Visscher D. W., Sarkar F., LoRusso P., Sakr W., Ottosen S., Wykes S., Crissman J. D. Immunohistologic evaluation of invasion-associated proteases in breast carcinoma. Mod Pathol. 1993 May;6(3):302–306. [PubMed] [Google Scholar]
  48. Westley B., Rochefort H. Estradiol induced proteins in the MCF7 human breast cancer cell line. Biochem Biophys Res Commun. 1979 Sep 27;90(2):410–416. doi: 10.1016/0006-291x(79)91250-6. [DOI] [PubMed] [Google Scholar]
  49. Winstanley J. H., Leinster S. J., Cooke T. G., Westley B. R., Platt-Higgins A. M., Rudland P. S. Prognostic significance of cathepsin-D in patients with breast cancer. Br J Cancer. 1993 Apr;67(4):767–772. doi: 10.1038/bjc.1993.139. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES